Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment
- 389 Downloads
We report our institutional observations of ten patients with advanced hepatocellular carcinoma (HCC) (seven and three were Child–Pugh class A and B, respectively) who received compassionate regorafenib therapy between June 2016 and January 2017. These patients did not fit the rigid criteria of a clinical trial and represented the use of regorafenib in an everyday clinic situation.
Regorafenib (160 mg P.O. daily) was administered to patients on a 4-week cycle (3 weeks on, 1 week off) until disease progression (assessed using mRECIST criteria) or discontinuation secondary to toxicity (assessed using CTCAE criteria). Relevant clinical data were abstracted from patient medical records and reviewed retrospectively.
The median duration of patient treatment was 6.6 weeks, and the median time to disease progression was 12.5 weeks. Most common treatment emergent adverse events were fatigue, diarrhea, and hand–foot skin reaction. Elevated AST and ALT were the most commonly observed laboratory-assessed adverse events, which reached grade 3 status in the Child–Pugh class B patients only. We observed intolerance to regorafenib treatment in one patient who had previously received a liver transplant. We also saw lithium toxicity in one patient receiving long-term lithium treatment, suggesting a potential and unexpected drug–drug interaction with regorafenib.
Taken together, our observations indicate that regorafenib is beneficial in the treatment of patients with advanced HCC who progressed on or demonstrated intolerance to sorafenib therapy; however, careful selection and close monitoring of patients is necessary to maximize the benefit while minimizing the toxicities of regorafenib treatment.
KeywordsHepatocellular carcinoma HCC Regorafenib Observation Pretreated
Compliance with ethical standards
Conflict of interest
Dr. Aiwu Ruth He serves as a speaker in Bayer’s speaker’s program. All other authors have no conflicts of interest to report. There is no disclosure of potential conflicts of interest among all authors.
Research involving human participants and/or animals
The study involves medical chart review of patients. The study is carried out under IRB-approved protocol with the titile of “Establishment of the High Quality Tumor Biobank and Clinical Database (2007- 345)”.
Informed consent is waived for this retrospective medical chart review.
No funding is obtained for this study.
- 4.Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34. doi: 10.1016/S1470-2045(08)70285-7 CrossRefPubMedGoogle Scholar
- 10.Llovet JM, Decaens T, Raoul JL et al (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509–3516. doi: 10.1200/JCO.2012.47.3009 CrossRefPubMedGoogle Scholar
- 12.Zhu AX, Park JO, Ryoo BY et al (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomized, double-blind, multicentre, phase 3 trial. Lancet Oncol 16:859–870. doi: 10.1016/S1470-2045(15)00050-9 CrossRefPubMedGoogle Scholar
- 17.Drug safety labeling changes. US food and drug administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203085s007lbl.pdf. Accessed on 23 May 2017
- 25.Mross K, Frost A, Steinbild S et al (2012) A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18(9):2658–2667. doi: 10.1158/1078-0432.CCR-11-1900 CrossRefPubMedGoogle Scholar
- 26.Ducreux M, Öhler L, Scheithauer W et al (2017) Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: an interim analysis (IA) from the prospective, observational CORRELATE study. J Clin Oncol 35(4S):700–700. doi: 10.1200/JCO.2017.35.4_suppl.700 CrossRefGoogle Scholar